Investor Relations

Emisphere Technologies is a Drug Delivery Company whose core business strategy is to partner its proprietary drug delivery technology and license Eligen B12.  Our thirty year history has made us the established leader in converting injectable therapeutics into advanced oral therapeutics. Utilizing our experience in researching, developing and manufacturing a number of fully characterized carriers in our extensive library, our partners leverage our expertise to employ our unique intracellular delivery mechanism to advance their portfolio and create differentiated line extensions.

Our capabilities range from early proof of concept, to extensive development and commercial capabilities. Emisphere’s technology can enhance the clinical profile of both pre-market and currently marketed products.  Further, our broad-based proprietary oral drug delivery platform provides significant increases in bioavailability, facilitates the enhanced absorption of small and large molecules without altering their chemical form, and maintains their biological integrity or pharmacological properties.  Finally, it is especially useful for oral delivery of peptides, proteins, oligonucleotides and oligosaccharides.

OT : EMIS
0.36
+ 0.03 (+9.06%)

3:52 PM ET on Dec 14, 2017
Delayed at least 20 minutes.


FOLLOW US